CMA removes barrier to availability of vital treatments on the NHS
The CMA acts to help NHS patients access combination therapies used to treat serious medical conditions.
Stay updated with breaking news from Medicines Value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The CMA acts to help NHS patients access combination therapies used to treat serious medical conditions.
The Competition and Markets Authority (CMA) has today issued a statement clarifying that certain types of engagements between competing drug firms working on 'combination therapies' will not be prioritized for investigation - making it easier for drug firms to work together to develop vital treatments for use in the NHS.
Announced today, ALTURiX - a rapidly-growing British pharmaceutical company - has been granted an expanded indication in the UK for CEYESTO® 3mg Tablets, an immediate release form of melatonin. CEYESTO® has been available in the UK for over a year for the short term treatment of jet lag in adults, and has now also ...
Deal is part of mission to increase options available prescribers, patients and the NHS - News - PharmaTimes